Drugs / SynVac
Follow
re-read 3 minutes ago
SynVac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000775 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SynVac | “SynVac is a synthetic candidate vaccine based on eight V3-derived peptides attached to a heptalysyl core to form radial octamers.” NCT00000775 ↗ |
| Known as | HIV-1 MN Octameric V3 Peptide Vaccine | “A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)” NCT00000775 ↗ |
| Known as | rgp120/HIV-1MN octameric V3 peptide vaccine | “rgp120/HIV-1MN octameric V3 peptide vaccine (SynVac) in healthy volunteers.” NCT00000775 ↗ |
| Known as | UBI SynVac | “A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)” NCT00000775 ↗ |
| Modality | Vaccine | “SynVac is a synthetic candidate vaccine” NCT00000775 ↗ |
| Route | Intramuscular | “Intramuscular injections are given on day 0, 28, and 168.” NCT00000775 ↗ |